Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers.
Scope of the Report:
This report studies the Celiac Disease Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Celiac Disease Drugs market by product type and applications/end industries.
The global Celiac Disease Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2018 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Celiac Disease Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2018 and will be xx million USD in 2024, with a CAGR of xx%.
Market Segment by Companies, this report covers:
Roche
Merck
Johnson & Johnson
BiolineRx
Pfizer
Innovate Biopharmaceuticals
ImmusanT
Novartis
Immunomedics
Market Segment by Regions, regional analysis covers:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers:
First Line of Treatment
Second Line of Treatment
Market Segment by Applications, can be divided into:
Hospital
Research